Good News for Cleveland BioLabs Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
April 17, 2014 - Zacks via Yahoo! Finance
Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102 Cleveland BioLabs, Inc. today announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients ...
April 16, 2014 - Marketwired via Yahoo! Finance